NEW YORK, May 22, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC.PK) announced today that it has entered a sponsored research agreement with the Institute for Cell Engineering and Regenerative Medicine (ICERM) at the University of Florida. A portion of the collaborative work will be to explore the physiological characteristics of the adult autologous vascular cells that are also referred to as stromal vascular fraction cells which form the basis of the IntelliCell product. The company also intends to explore combination therapies with patent pending bio-engineered products under development. The Company believes that the IntelliCell product is an efficient cellular delivery platform for a variety of therapeutic applications and will look to partner with technology developers.
Said Jon Dobson, Ph.D., Professor of biomedical engineering and biomaterials at the University of Florida, "We are pleased to be working with IntelliCell. Their technology is innovative and appears to hold promise for future regenerative medicine applications. The use of adult autologous (your own) stem cells to repair and regenerate tissues are of great interest to personalized medicine researchers." Professor Dobson is a leading researcher in bionanotechnology and nanomedicine applications and apart from regenerative medicine, his work also spans across fields as diverse as gene therapy, stem cell therapy and tumor targeting. He is also the Director of the newly formed Institute for Cell Engineering and Regenerative Medicine at the University of Florida.
Dr. Steven Victor, CEO of IntelliCell, added "This is a very exciting time for regenerative medicine companies. We are looking forward to long and productive research collaboration with the University of Florida and Professor Dobson. IntelliCell believes that important contributions for better medicine will result from research collaborations with our university research colleagues." Robert Sexauer, Executive Vice President, ICBS Research, stated that "we would like to take a thought leadership position by working closely with those at the vanguard of regenerative medicine development."
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology licensing agreements with technology developers, universities, and international business entities.
About University of Florida
The University of Florida is one of the nation's largest public universities. A member of the Association of American Universities, UF receives more than $619 million annually in sponsored research funding. Through its research and other activities, UF contributes more than $8.76 billion a year to Florida's economy and has a total employment impact of more than 100,000 jobs statewide. www.ufl.edu.University of Florida Research: Working for Florida.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact: TClemensen@rubensteinir.com
University of Florida
College of Engineering
Email Contact: firstname.lastname@example.org
SOURCE IntelliCell BioSciences, Inc.